Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Neoplasms 14Carcinoma, Hepatocellular 13Recurrence 12Brain Neoplasms 12Prostatic Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Glioblastoma 10Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Lymphocytic, Chronic, B-Cell 8Gliosarcoma 8Waldenstrom Macroglobulinemia 7Sarcoma 7Lung Neoplasms 7Glioma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Liver Neoplasms 5Kidney Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, Follicular 4

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21Standard of Care 20Sirolimus 20Azacitidine 20venetoclax 19Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × Thalidomide × Clear all
NCT00215943 2014-04-17

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

H. Lee Moffitt Cancer Center and Research Institute

Phase 3 Terminated
90 enrolled 10 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡